Con­cor­dia’s int’l unit un­der U.K. Com­pe­ti­tion in­quiry

Stockwatch Daily - - FRONT PAGE - Mr. Adam Peeler re­ports

THE U.K. Com­pe­ti­tion and Mar­kets Author­ity (CMA) is in­ves­ti­gat­ing new is­sues in re­la­tion to the U.K. phar­ma­ceu­ti­cal sec­tor, and that Con­cor­dia In­ter­na­tional Corp.’s in­ter­na­tional seg­ment and cer­tain of its prod­ucts are part of the in­quiry.

The in­ves­ti­ga­tion is at an early, in­for­ma­tion-gath­er­ing stage and the CMA has con­firmed that, at this time, it has not reached any con­clu­sions on whether com­pe­ti­tion law has been in­fringed.

The com­pany com­mented, “We are work­ing to bet­ter un­der­stand the CMA’s po­si­tion and we will con­tinue to work con­struc­tively to re­solve these mat­ters.”

The CMA’s in­ves­ti­ga­tion in­cludes mat­ters that pre­date Con­cor­dia’s own­er­ship of the in­ter­na­tional seg­ment. Con­cor­dia ac­quired the in­ter­na­tional seg­ment as a re­sult of its trans­ac­tion to pur­chase Amdipharm Mer­cury Ltd., which closed on Oct. 21, 2015.

About Con­cor­dia In­ter­na­tional Corp.

Con­cor­dia is an in­ter­na­tional spe­cialty phar­ma­ceu­ti­cal com­pany with a di­ver­si­fied port­fo­lio of more than 200 patented and off-patent prod­ucts, and sales in more than 90 coun­tries. Going for­ward, the com­pany is fo­cused on be­com­ing a leader in Euro­pean spe­cialty, off-patent medicines.

Con­cor­dia op­er­ates out of fa­cil­i­ties in Oakville, Ont., and, through its sub­sidiaries, op­er­ates out of fa­cil­i­ties in Bridgetown, Bar­ba­dos; Lon­don, Eng­land; and Mum­bai, India.

We seek Safe Har­bor.

Dou­glas Nor­man Deeth, Rochelle Fuhrmann, Itzhak Krin­sky, Jor­dan M Kupin­sky, Al­lan Ober­man, Francis Perier, Pa­trick Vink

(CXR) Shares: 51,282,675

Newspapers in English

Newspapers from Canada

© PressReader. All rights reserved.